Cargando…
The Tropomyosin Family as Novel Biomarkers in Relation to Poor Prognosis in Glioma
SIMPLE SUMMARY: Due to the malignant features of glioma, current interventions result in limited treatment effects and poor prognoses for all patients. The functions of the tropomyosin (TPM) family in tumors and cancers have been explored. However, striking differences have been observed. This study...
Autores principales: | Huang, Ke, Wang, Huihui, Xu, Jia, Xu, Ruiming, Liu, Zelin, Li, Yi, Xu, Zhaoqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332389/ https://www.ncbi.nlm.nih.gov/pubmed/35892971 http://dx.doi.org/10.3390/biology11081115 |
Ejemplares similares
-
Identification of therapeutic targets and prognostic biomarkers among frizzled family genes in glioma
por: Huang, Ke, et al.
Publicado: (2023) -
SESN2 Could Be a Potential Marker for Diagnosis and Prognosis in Glioma
por: Xu, Lingdan, et al.
Publicado: (2023) -
MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma
por: Sun, Jin-Zhang, et al.
Publicado: (2021) -
Research Advances in the Role of the Tropomyosin Family in Cancer
por: Meng, Yucheng, et al.
Publicado: (2023) -
Increased Expression of Homeobox 5 Predicts Poor Prognosis: A Potential Prognostic Biomarker for Glioma
por: Xu, Chengran, et al.
Publicado: (2022)